CRINETICS PHARMACEUTICALS IN (CRNX) Earnings History & Surprises
NASDAQ:CRNX • US22663K1079
37.35 USD
-0.87 (-2.28%)
At close: Mar 10, 2026
37.51 USD
+0.16 (+0.43%)
After Hours: 3/10/2026, 8:15:59 PM
Past quarterly earnings results for CRINETICS PHARMACEUTICALS IN (CRNX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$1.27
Revenue Estimate8.371M
Last Reported
Release DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.29
EPS Surprise 7.51%
Revenue Surprise 27.48%
Beat Rate
38%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.29 | -1.39 | 7.51% | -46.59% | 6.161M | 4.833M | 27.48% | - |
| Q3 2025 | -1.38 | -1.28 | -7.76% | -43.75% | 143K | 370.892K | -61.44% | - |
| Q2 2025 | -1.23 | -1.12 | -9.79% | -30.85% | 1.031M | 131.753K | 682.52% | 158.40% |
| Q1 2025 | -1.04 | -0.96 | -8.34% | -11.83% | 361K | 92.728K | 289.31% | -43.59% |
| Q4 2024 | -0.88 | -0.91 | 2.94% | 2.22% | 738.113K | -100.00% | - | |
| Q3 2024 | -0.96 | -0.93 | -3.35% | 4.95% | 244.8K | -100.00% | -100.00% | |
| Q2 2024 | -0.94 | -0.88 | -7.29% | - | 399K | 520.2K | -23.30% | -59.62% |
| Q1 2024 | -0.93 | -0.83 | -12.64% | -9.41% | 640K | 260.671K | 145.52% | -76.11% |
| Q4 2023 | -0.90 | -0.88 | -2.31% | -7.14% | 265.2K | -100.00% | -100.00% | |
| Q3 2023 | -1.01 | -0.88 | -15.29% | -29.49% | 346K | 125.97K | 174.67% | -24.78% |
| Q2 2023 | -0.94 | -0.87 | -7.46% | -16.05% | 988K | 574.433K | 72.00% | 124.55% |
| Q1 2023 | -0.85 | -0.83 | -2.64% | -19.72% | 2.679M | 351.023K | 663.20% | -14.41% |
| Q4 2022 | -0.84 | -0.84 | -0.23% | -23.53% | 710K | 255K | 178.43% | -34.26% |
| Q3 2022 | -0.78 | -0.85 | 8.05% | -6.85% | 460K | 170.003K | 170.58% | - |
| Q2 2022 | -0.81 | -0.69 | -17.94% | -15.71% | 440K | 612K | -28.10% | - |
| Q1 2022 | -0.71 | -0.59 | -20.01% | -2.90% | 3.13M | 5.304M | -40.99% | - |
| Q4 2021 | -0.68 | -0.64 | -6.67% | -3.03% | 1.08M | - | - | |
| Q3 2021 | -0.73 | -0.73 | 0.04% | -30.36% | - | - | ||
| Q2 2021 | -0.70 | -0.62 | -12.50% | -32.08% | - | - | ||
| Q1 2021 | -0.69 | -0.67 | -2.50% | 2.82% | - | -100.00% | ||
| Q4 2020 | -0.66 | -0.59 | -11.95% | - | - | - | ||
| Q3 2020 | -0.56 | -0.54 | -4.38% | - | - | - | ||
| Q2 2020 | -0.53 | -0.58 | 8.20% | - | - | - | ||
| Q1 2020 | -0.71 | -0.64 | -10.49% | - | 70K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
1
Average EPS beat (4)
-4.59%
Max EPS beat (4)
7.51%
Min EPS beat (4)
-9.79%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
234.47%
Max Revenue beat (4)
682.52%
Min Revenue beat (4)
-61.44%
Analysis
In the last 4 quarters, CRNX has beaten EPS estimates in 1 out of 4 releases
CRNX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, CRNX reported -4.6% below the EPS estimates on average.
In the last 4 quarters, CRNX has beaten the revenue estimates by 234.5% on average.
CRINETICS PHARMACEUTICALS IN / CRNX Earnings FAQ
When did CRINETICS PHARMACEUTICALS IN (CRNX) report earnings last quarter?
CRINETICS PHARMACEUTICALS IN (CRNX) last reported earnings on 2/26/2026.
Can you provide information on whether CRINETICS PHARMACEUTICALS IN beat earnings estimates in the last quarter?
CRINETICS PHARMACEUTICALS IN (CRNX) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does CRNX stock beat earnings estimates?
In the last 4 quarters, CRINETICS PHARMACEUTICALS IN (CRNX) has beaten EPS estimates in 1 out of 4 releases.